

REMARKS

Claims 1 to 41 are pending in this application. Claims 1, 3, 5-11, 18, 19, and 24-41 stand rejected. Claims 2, 4, 12-17 and 20 are objected to but would be allowable if written in independent form.

At paragraph 2 of the Action, the Examiner states that the application does not include an abstract as required by 34 CFR 1.72. Applicants point out that the present application is a National filing of PCT Application No. PCT/US2004/028655. As seen from the attached page from the PCT publication, this application did include an Abstract when it published. Nonetheless, Applicants have amended the specification to include an Abstract. The Abstract is identical to that filed in the PCT. Accordingly, no new matter has been added.

At paragraph 4 of the Action, the Examiner rejects claims 21-30 and 32 to 37 for lack of enablement. The claims at issue are method of treatment claims. Applicants make no admissions with regard to the rejection, but nonetheless have cancelled claims 21-23, 25-29, 34-37, and 40-41 and amended claim 24 to address the Examiner's concerns. Applicants respectfully submit that there is ample support in the literature and the specification for the indications of the amended claims.

At paragraph 5, the Examiner has rejected claims 1, 3, 5-11, 18, 19 and 21-41 as anticipated. The Examiner states:

"Claims 1, 3, 5-11, 18, 19 and 21-41 are rejected under 35 U.S.C. 102(b) as being anticipated by Rasmussen (J. Med Chem., cited on applicant's form 1449). Rasmussen discloses Azasteroids having binding affinity to androgen receptors. The compounds, 10ap and 10 aq (see table II on page 2300) disclosed by Rasmussen anticipate the instant claims when a and b represent a single bond, X, Y, Z, V and W all represent hydrogen, R1 represents an alkyl group, U represents N and D represents either O or S in the instant compounds of formula 1. It is of note that both O and S belong to the same class of chalcogens."


Applicants respectfully submit that their amendments to the claims render this issue moot.

At paragraph 6, the Examiner identifies claims 2, 4, 12-17 and 20 as objected to for being dependent upon a rejected base claim, but would be allowable if written in independent form. In response, Applicants have amended the claims as indicated by the Examiner.

Having addressed all of the outstanding objections and rejections, Applicants respectfully submit that the application is in condition for allowance and passage thereto is earnestly requested. The Examiner is invited to contact the undersigned attorney at the telephone number provided below if such would advance the prosecution of this application.

Respectfully submitted,

By:


Curtis C. Panzer
Reg. No. 33,752
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065
Tel. (732) 594-3199

20
Date: May 19, 2008